TOP TEN perturbations for 39066_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39066_at
Selected probe(set): 212713_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39066_at (212713_at) across 6674 perturbations tested by GENEVESTIGATOR:
stem cell differentiation study 41 (T3pi) / undifferentiated hES-T3 cell sample
Relative Expression (log2-ratio):6.0406876Number of Samples:2 / 3
| Experimental | stem cell differentiation study 41 (T3pi) |
| Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype. | |
| Control | undifferentiated hES-T3 cell sample |
| Undifferentiated human embryonic stem cells T3. |
ovarian tumor study 28 (carcinosarcoma) / ovarian tumor study 28 (adenocarcinoma)
Relative Expression (log2-ratio):5.359334Number of Samples:2 / 3
| Experimental | ovarian tumor study 28 (carcinosarcoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma. | |
| Control | ovarian tumor study 28 (adenocarcinoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with adenocarcinoma. |
pancreatic islet study 3 (re-differentiated; PPRF; 4d) / normal pancreatic islet sample
Relative Expression (log2-ratio):5.308461Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 4d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 4 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
pancreatic islet study 3 (re-differentiated; PPRF; 6d) / normal pancreatic islet sample
Relative Expression (log2-ratio):5.1318445Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 6d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 6 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
ovarian tumor study 28 (carcinosarcoma) / ovarian tumor study 28 (clear cell adenocarcinoma)
Relative Expression (log2-ratio):5.0921335Number of Samples:2 / 6
| Experimental | ovarian tumor study 28 (carcinosarcoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma. | |
| Control | ovarian tumor study 28 (clear cell adenocarcinoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with clear cell adenocarcinoma. |
pancreatic islet study 3 (re-differentiated; PPRF; 2d) / normal pancreatic islet sample
Relative Expression (log2-ratio):4.989522Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 2d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 2 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
ovarian tumor study 28 (endometrioid carcinoma) / ovarian tumor study 28 (carcinosarcoma)
Relative Expression (log2-ratio):-4.9775915Number of Samples:6 / 2
| Experimental | ovarian tumor study 28 (endometrioid carcinoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with endometrioid carcinoma. | |
| Control | ovarian tumor study 28 (carcinosarcoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma. |
ovarian tumor study 28 (mucocarcinoid tumor) / ovarian tumor study 28 (carcinosarcoma)
Relative Expression (log2-ratio):-4.8591156Number of Samples:7 / 2
| Experimental | ovarian tumor study 28 (mucocarcinoid tumor) |
| Primary tumor tissue sample obtained from the ovary of female patients with malignant mucocarcinoid tumor. | |
| Control | ovarian tumor study 28 (carcinosarcoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma. |
ovarian tumor study 28 (serous cystadenocarcinoma) / ovarian tumor study 28 (carcinosarcoma)
Relative Expression (log2-ratio):-4.6197863Number of Samples:71 / 2
| Experimental | ovarian tumor study 28 (serous cystadenocarcinoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with malignant serous cystadenocarcinoma. | |
| Control | ovarian tumor study 28 (carcinosarcoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma. |
hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (10d)
Relative Expression (log2-ratio):4.602234Number of Samples:3 / 3
| Experimental | hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) |
| Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A. | |
| Control | hepatocyte-like cell differentiation study 1 (10d) |
| Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to hepatic specification stage for 10 days. |